2-Bromopyridine → 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-3-methyl-8-pyridin-2-yl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one
반응식
[CH3:1][N:2]1[CH:6]=[C:5]([N:7]2[C:19]3[C:18]4[CH:17]=[C:16](B5OC(C)(C)C(C)(C)O5)[CH:15]=[CH:14][C:13]=4[N:12]=[CH:11][C:10]=3[N:9]([CH3:29])[C:8]2=[O:30])[C:4]([CH3:31])=[N:3]1.Br[C:33]1[CH:38]=[CH:37][CH:36]=[CH:35][N:34]=1>>[CH3:1][N:2]1[CH:6]=[C:5]([N:7]2[C:19]3[C:18]4[CH:17]=[C:16]([C:33]5[CH:38]=[CH:37][CH:36]=[CH:35][N:34]=5)[CH:15]=[CH:14][C:13]=4[N:12]=[CH:11][C:10]=3[N:9]([CH3:29])[C:8]2=[O:30])[C:4]([CH3:31])=[N:3]1참가 물질
3
실험 절차
The title compound was synthesized in a similar manner as described in Example 112 using 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (Stage 114.1.1, 34.5 mg, 0.082 mmol) and 2-bromopyridine (Aldrich, Buchs, Switzerland, 0.011 ml, 0.114 mmol) to give the title compound as a white solid. (HPLC: tR 2.25 min (Method A); M+H=371 MS-ES; 1H-NMR (d6-DMSO, 400 MHz) 8.98 (s, 1H), 8.67-8.61 (m, 1H), 8.30-8.24 (m, 1H), 8.17-8.06 (m, 3H), 7.94-7.86 (m, 1H), 7.67-7.61 (m, 1H), 7.39-7.32 (m, 1H), 3.95 (s, 3H), 3.57 (s, 3H), 1.95 (s, 3H))